文献速递睡眠呼吸障碍小儿耳鼻咽喉

舌下神经刺激治疗唐氏综合征儿童及青少年的长期随访

Upper Airway Stimulation for Children and Adolescents with Down Syndrome: Long-Term Follow-Up.
PubMed 文献 · Laryngoscope · 2024-10-09

一项前瞻性单组多中心队列研究纳入42例唐氏综合征合并重度持续性阻塞性睡眠呼吸暂停的青少年患者,评估舌下神经刺激植入后长期疗效。33例完成长期随访,平均随访4.0年,呼吸暂停低通气指数(AHI)较基线平均下降15.7次/小时,治疗应答率87.9%。结论认为患者可能在长期随访中持续获益,需未来研究评估神经认知和生活质量等结局。

要点

  • 舌下神经刺激植入后长期随访AHI平均下降15.7次/小时。
  • 长期随访治疗应答率87.9%(29/33),1年时为69.7%(23/33)。
  • 需未来研究评估神经认知和生活质量等长期结局。

核心结论

  • 唐氏综合征合并重度持续性阻塞性睡眠呼吸暂停患者接受舌下神经刺激植入后,长期随访中可能持续出现多导睡眠图参数改善。
  • 未来需开展研究评估该人群的神经认知和生活质量等其他长期结局。

研究设计与样本

  • 前瞻性单组多中心队列研究,2015年至2021年纳入42例唐氏综合征合并重度持续性阻塞性睡眠呼吸暂停的青少年患者,随访1年。
  • 本报告评估该队列的长期结局,患者在多导睡眠图三个时间点接受评估:植入前(时间点1)、植入后1年(时间点2)和长期随访(时间点3)。
  • 证据等级为3级。

主要发现

  • 42例患者中33例有长期随访数据,时间点3平均(标准差)为植入后4.0(1.9)年。
  • 以AHI较时间点1下降50%定义治疗应答,时间点2应答率为69.7%(23/33),时间点3为87.9%(29/33)。
  • AHI较时间点1平均(标准差)下降:时间点2为12.7(13.4)次/小时,时间点3为15.7(13.1)次/小时。
  • 时间点1至2的AHI平均百分比变化为-51.1%(95% CI:-32.8%至-69.3%),时间点1至3为-59.6%(95% CI:-42.0%至-77.3%)。

临床怎么用

  • 研究结论指出,接受舌下神经刺激植入的唐氏综合征合并重度持续性阻塞性睡眠呼吸暂停患者,在长期随访中可能持续出现多导睡眠图参数改善。
  • 原文未据此给出推荐。

局限性

  • 未来需开展研究评估该人群的神经认知和生活质量等其他长期结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE(S): Hypoglossal nerve stimulation (HGNS) is safe and effective for patients with Down syndrome (DS) and severe persistent obstructive sleep apnea (OSA). Long-term outcomes for this patient population have not been evaluated. METHODS: A prospective single-group multicenter cohort study with 1-year follow-up was conducted between 2015 and 2021 among 42 adolescent patients with DS and severe persistent OSA. Here, we evaluate long-term outcomes in this patient cohort. Patients were evaluated with polysomnogram (PSG) at three timepoints: pre-implantation (timepoint 1), 1-year post-implantation (timepoint 2), and long-term follow-up (timepoint 3). RESULTS: Long-term follow-up data were available for 33 of 42 patients. Mean (SD) of timepoint 3 was 4.0 (1.9) years after implantation. Using a therapy response definition of a 50% decrease in Apnea Hypopnea INdez (AHI) from timepoint 1, the response rate was 69.7% (23/33) at timepoint 2 and 87.9% (29/33) at timepoint 3. From timepoint 1, there was a mean (SD) decrease in AHI of 12.7 (13.4) events/h at timepoint 2 and 15.7 (13.1) events/h at timepoint 3. The mean percentage change in AHI between timepoints 1 and 2 was -51.1% (95% CI: -32.8% to -69.3%) and between timepoints 1 and 3 was -59.6% (95% CI: -42.0% to -77.3%). CONCLUSION: Patients with DS and severe persistent OSA who undergo HGNS implantation may continue to experience improvement in PSG parameters at long-term follow-up. Future studies are needed to assess additional long-term outcomes in this patient population, including neurocognition and quality of life. LEVEL OF EVIDENCE: 3 Laryngoscope, 135:1218-1222, 2025.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Larrow DR, Marcus KS, Gipson K, et al. Upper Airway Stimulation for Children and Adolescents with Down Syndrome: Long-Term Follow-Up. Laryngoscope. 2024. PMID: 39381939. doi:10.1002/lary.31828

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。